EBS 8-K 2026-10-16

Emergent BioSolutions Inc. (EBS) 8-K dated 2026-10-16 — accession 0001367644-26-000098. This URL is the filing, not the EBS hub.

Emergent BioSolutions Inc. (EBS) is a drug manufacturers - specialty & generic company listed on US.

Emergent BioSolutions Inc. filed a 8-K on 2026-10-16. Accession 0001367644-26-000098.

Cached items: 5.02, 9.01. EDGAR remains the official archive; Lician keeps this accession as its own indexable page so Google can recrawl the form, not a ticker dump.

Latest reported EBS revenue for 2025-12-31 was $742.9M. Net income was $52.6M. Revenue was down 28.8% from 2024-12-31 to 2025-12-31. EBS currently screens at market cap $416.4M.

Not investment advice. The EBS SEC hub lists recent forms. The stock page is the research view.